@article{cbdee196d2c545d286522bf37dc45c28,
title = "Chemotherapy and Tyrosine Kinase Inhibitors in the last month of life in patients with metastatic lung cancer: A patient file study in the Netherlands",
keywords = "aggressive care, cancer treatment, chemotherapy, end of life, metastatic lung cancer, Tyrosine Kinase Inhibitors, END-OF-LIFE, PALLIATIVE CHEMOTHERAPY, CARE, ONCOLOGY, QUALITY, OSIMERTINIB, GEFITINIB, DOCETAXEL, NIVOLUMAB, ERLOTINIB",
author = "Adinda Mieras and Annemarie Becker-Commissaris and Pasman, {H. Roeline W.} and Dingemans, {Anne-Marie M. C.} and Edith Kok and Robin Cornelissen and Wouter Jacobs and {van den Berg}, {Jan Willem} and Alle Welling and Bogaarts, {Brigitte A. H. A.} and Lemke Pronk and Onwuteaka-Philipsen, {Bregje D.}",
year = "2020",
month = mar,
doi = "10.1111/ecc.13210",
language = "English",
volume = "29",
journal = "European Journal of Cancer Care",
issn = "0961-5423",
publisher = "Wiley",
number = "2",
}